PARIS–( BUSINESS WIRE )– Regulatory News:
Hospitalex, the leading Italian manufacturer of medical devices and one of its subsidiaries Alico Scientific (Iconysys SA) ( Euronext (EPA:)Growth Paris: Alico), today announces that it has been awarded a public tender to purchase… Gaetano Martino University Hospital In Messina, Italy.
Contract value 668 thousand euros Over a period of three years, including the option to extend it for an additional two years, bringing the total potential value to 1.025 million euros. The tender covers the supply of alcohol for medical and hospital use, which is a vital component of maintaining high standards of healthcare services.
Hospitex is certified as a fiscal warehouse for alcohol by the Italian Customs Agency, a distinction that is among the most difficult to obtain due to complex regulatory, logistical, infrastructural and administrative requirements. This accreditation demonstrates Hospitex’s operational excellence and positions the company as a trusted supplier capable of operating in highly complex regulated environments.
The company’s expertise in hydroalcoholic solutions and pure alcohol production extends far beyond Italy, with Hospitex serving healthcare institutions across Europe, underscoring its ability to deliver reliable, high-quality medical alcohol solutions on a large scale.
Francesco Tresolini, CEO of Hospitalexmale: “Obtaining this tender reaffirms our leadership in the healthcare sector and our ability to overcome the complexities of regulatory and logistical frameworks. The approval of our financial warehouse highlights our operational excellence and demonstrates our readiness to meet the needs of both local and international clients. We are proud to partner with Gaetano Martino University Hospital and remain committed to providing vital supplies that support excellence in healthcare.”
This achievement strengthens ALIKO SCIENTIFIC’s strategic position in the healthcare and life sciences sectors, and supports its growth objectives and commitment to innovation.
About ALIKO SCIENTIFIC (Ikonisys SA)
ALIKO SCIENTIFIC is headquartered in Paris It is the parent company of an international ecosystem of companies dedicated to developing oncology diagnostics. Listed on Euronext Growth Paris under the symbol ALIKO, the company coordinates industrial, financial and research activities through its subsidiaries: Ikonisys Inc. (USA) and Hospitex International (Italy). ALIKO SCIENTIFIC’s mission is to innovate cancer diagnostics by uniting cutting-edge technologies, resources and strategic investments to create a global center of excellence in oncology.
For more information, visit: www.alikoscientific.com
About Iconysys
Ikonisys is a global leader in automated diagnostics, specializing in fluorescence in situ hybridization (FISH) and circulating tumor cell (CTC) detection. Leveraging advanced artificial intelligence (AI) and a fully automated microscopy platform, Ikonisys delivers unparalleled accuracy, scalability and efficiency in cancer diagnosis and treatment monitoring. Known as a pioneer in the automation of rare cell detection, Ikonisys is at the forefront of personalized medicine, empowering clinicians to deliver targeted treatments and improve patient outcomes.
For more information, visit: www.ikonisys.com
About Hospitalex
Hospitex, headquartered in Florence, Italy, is a global leader in cell science innovation. The company conducts research, development and production in-house, thus ensuring the highest quality standards. Hospitics offers the world’s most advanced liquid-based cytology (LBC) technology, capable of processing any cellular sample with unparalleled accuracy. Hospitex is uniquely positioned as the only company fully prepared for seamless digital integration, paving the way for a transformative future in cell diagnostics.
For more information, visit: www.hospitex.com
Disclaimer
This press release contains forward-looking statements about the Company’s prospects and development. These statements are sometimes identified by the use of the future tense, the subjunctive mood and forward-looking words such as “believes”, “aims to”, “anticipates”, “intends”, “estimates”, “believes”, and “should”. “, “could”, “will” or “will” or, where appropriate, the negative of these terms or any other similar variants or expressions. This information is not historical data and should not be construed as a guarantee that the facts and data stated will occur. This information refers to statements, assumptions and estimates that the Company considers reasonable and is subject to change or modification due to uncertainties related to the economic, financial, competitive and regulatory environment. This information contains statements regarding the Company’s intentions, estimates and objectives relating in particular to market, strategy, growth and results and the financial condition and cash flow of the Company. The forward-looking information contained in this press release is provided only as of the date of this press release. The Company undertakes no obligation to update any forward-looking information contained in this press release, except as required by applicable law or regulation. The Company operates in a competitive and competitive environment change, and therefore cannot anticipate all of the risks, uncertainties or other factors that may affect its business or their potential impact on its business or the extent to which any single risk or combination of risks could cause results to differ materially from those expressed in any Forward-looking information: Please note that none of this forward-looking information constitutes a guarantee of actual results.
View source version on Businesswire.com: https://www.businesswire.com/news/home/20250114677393/en/
Iconesis
Alessandro Mauri
CFO
[email protected]
newcap
Louis Victor DeLouvrier/Aurélie Manafarire
Investor relations
[email protected]
Tel: +33 (0)1 44 71 94 94
newcap
Nicola Mérigeau
Media relations
[email protected]
phone: +33 (0)1 44 71 94 98
Source: Iconysys
https://i-invdn-com.investing.com/redesign/images/seo/investing_300X300.png
Source link